<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768089</url>
  </required_header>
  <id_info>
    <org_study_id>VX17-121-001</org_study_id>
    <secondary_id>2018-000126-55</secondary_id>
    <nct_id>NCT03768089</nct_id>
  </id_info>
  <brief_title>Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy
      subjects and in subjects with cystic fibrosis (CF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">May 3, 2019</completion_date>
  <primary_completion_date type="Actual">May 3, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From baseline up to Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-121,TEZ and metabolites, IVA and metabolites</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-121, TEZ and metabolites, IVA and metabolites</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-121, TEZ and metabolites, IVA and metabolites</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D only: Absolute change in sweat chloride concentrations</measure>
    <time_frame>From baseline through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D only: Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>From baseline through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A: VX-121 in Healthy Subjects (HS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: VX-121 in HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-dose escalation of VX-121 in TC with TEZ/IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: VX-121 in TC with TEZ/IVA in subjects with CF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-121 in TC with TEZ/IVA in subjects with CF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-121</intervention_name>
    <description>VX-121 tablet or suspension for oral administration.</description>
    <arm_group_label>Part A: VX-121 in Healthy Subjects (HS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-121</intervention_name>
    <description>VX-121 suspension for oral administration.</description>
    <arm_group_label>Part B: VX-121 in HS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-121</intervention_name>
    <description>VX-121 tablet for oral administration.</description>
    <arm_group_label>Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_label>Part D: VX-121 in TC with TEZ/IVA in subjects with CF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ/IVA</intervention_name>
    <description>100 milligram (mg) TEZ/150-mg IVA, fixed-dose combination (FDC) tablet for oral administration.</description>
    <arm_group_label>Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <other_name>VX-661/VX-770</other_name>
    <other_name>Tezacaftor/Ivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ/IVA</intervention_name>
    <description>100 mg TEZ/150-mg IVA, FDC tablet for oral administration.</description>
    <arm_group_label>Part D: VX-121 in TC with TEZ/IVA in subjects with CF</arm_group_label>
    <other_name>VX-661/VX-770</other_name>
    <other_name>Tezacaftor/Ivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>150-mg film-coated tablet for oral administration.</description>
    <arm_group_label>Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS</arm_group_label>
    <arm_group_label>Part D: VX-121 in TC with TEZ/IVA in subjects with CF</arm_group_label>
    <other_name>VX-770</other_name>
    <other_name>Ivacaftor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo</intervention_name>
    <description>Matched placebo.</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_label>Part D: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Part A, B, and C: Healthy Volunteers

               -  Female subjects must be of non-childbearing potential

               -  Between the ages of 18 and 55 years, inclusive

               -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight
                  &gt;50 kg

          -  Part D: Subjects with CF

               -  Heterozygous for F508del and an MF mutation (F/MF)

               -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

               -  Body weight ≥35 kg

        Key Exclusion Criteria:

          -  Part A, B and C: Healthy Volunteers

               -  Any condition possibly affecting drug absorption

               -  History of febrile illness or other acute illness within 5 days before the first
                  study drug dose

          -  Part D: Subjects with CF

               -  History of clinically significant cirrhosis with or without portal hypertension

               -  History of solid organ or hematological transplantation

               -  Lung infection with organisms associated with a more rapid decline in pulmonary
                  status

        Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis van den Haag</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences Onderzoekscentrum UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <disposition_first_submitted>May 1, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 7, 2020</disposition_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

